Announcing AAPS and FDA Agreement to Build Quantitative Alzheimer’s Disease Model

Abstract

American Association of Pharmaceutical Scientists (AAPS) and Pharmacometrics, Office of Clinical Pharmacology, Food and Drug Administration (FDA) have a Cooperative Research and Development Agreement (CRADA) to build a quantitative Alzheimer’s Disease Model. AAPS is seeking fellows who are interested in applying quantitative ‘learning’ approaches for solving drug development and regulatory challenges. Specifically, the incumbent will work with the FDA Pharmacometrics group (Silver Spring, MD, USA) to develop and apply Alzheimer’s Disease Model to drug development. The fellowship is for 2 years. Requirements include an earned Pharm.D., Ph.D., M.D. or other professional doctorate related to pharmaceutical sciences or statistics. Clinical and pharmaceutical scientists with a good knowledge of pharmacokinetic and pharmacodynamic principles, an experience in mixed effects modeling including software skills (SAS, Splus, NONMEM, etc) or a statistician with a good knowledge of trial design and analyses principles with an interest in advanced innovative methods to explore clinical trial data are eligible for this fellowship. Proficiency with standard software (NONMEM, SAS or SPlus/R) is a must. This fellowship could also be a good opportunity for academicians who are willing to take 2 years of sabbatical leave. Good communication and writing skills are critical. Opportunities to learn and contribute in a dynamic team, to gain first-hand experience with regulatory aspects of Pharmacometrics, and to conduct and publish research in related areas are abundant. Candidates will need to be US permanent residents or citizens. Please forward your resume to: AAPS Attention: CRADA—Alzheimer’s Disease Model 2107 Wilson Boulevard, Suite 700 Arlington, VA 22201 crada@aaps.org www.aapspharmaceutica.com/crada Deadline for submissions: June 30, 2008